Pinos Korea builds value through trust-based international partnerships.
Our expanding global network enables us to execute NRDO commercialization with speed, scale, and credibility.

Key Strategic Partners:

  • Hwail Pharmaceuticals (South Korea)
    A KOSDAQ-listed pharmaceutical manufacturer with strong formulation, validation, and distribution capabilities.
    Hwail supports Pinos Korea's pharma-grade product development by providing GMP-level production, clinical planning resources, and early-stage market access within Korea and the broader Asian region.

  • IDT Australia
    A TGA-GMP certified pharmaceutical CDMO and global co-development partner.
    Together with IDT, we are establishing an international production and export pipeline for NRDO-based pharma-grade nutraceuticals, targeting the US and Asia-Pacific markets through joint regulatory, quality, and go-to-market infrastructure.

Vivaplan Kft. (Hungary)
A strategic partner based in Budapest, Vivaplan collaborates with Pinos Korea on cross-border consulting, technology commercialization, brand launching, cultural exchange, and investment facilitation between Korea and Central Europe.
This partnership strengthens our European expansion roadmap and creates synergy in both regulatory intelligence and market deployment.

This network-centric model strengthens our NRDO strategy by ensuring seamless alignment between innovation, compliance, and commercialization—across regions.